{"product_id":"the-next-generation-of-cholesterol-and-fat-lowering-treatments-what-patients-should-know-about-beyond-statin-therapies","title":"The Next Generation of Cholesterol and Fat-Lowering Treatments: What Patients Should Know About Beyond-Statin Therapies","description":"\u003cp\u003eThis review examines emerging therapies that go beyond traditional statin treatment to address residual cardiovascular risk. While statins effectively lower LDL cholesterol, many patients still face elevated risk from two other factors: lipoprotein(a) (Lp(a)) and triglycerides. The article covers new experimental drugs—including antisense oligonucleotides and monoclonal antibodies—that target Lp(a), apolipoprotein C-III, and angiopoietin-like protein 3, as well as the latest evidence on omega-3 fatty acids. Clinical outcome trials will ultimately determine whether these promising new approaches actually reduce cardiovascular events in patients.\u003c\/p\u003e\n\n\u003ch1\u003eThe Next Generation of Cholesterol and Fat-Lowering Treatments: What Patients Should Know About Beyond-Statin Therapies\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eIntroduction: The Limits of Current Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lpa\"\u003eLipoprotein(a): The Hidden Risk Factor\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#apoc3\"\u003eApolipoprotein C-III: A Key Regulator of Triglycerides\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#angptl3\"\u003eANGPTL3: A New Target for Multiple Lipid Problems\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#omega3\"\u003eOmega-3 Fatty Acids: Fish Oil's Evolving Role\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#future\"\u003eFuture Perspectives: What's on the Horizon\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eStatins lower LDL cholesterol and reduce major vascular events by 23% per 38.7 mg\/dL reduction, but many patients still face residual risk.\u003c\/li\u003e\n\u003cli\u003eLp(a) is genetically determined, largely unaffected by lifestyle, and levels above 50 mg\/dL are considered elevated.\u003c\/li\u003e\n\u003cli\u003eMendelian randomization shows elevated Lp(a) and triglycerides are independent causal risk factors for cardiovascular disease.\u003c\/li\u003e\n\u003cli\u003eExperimental drugs targeting Lp(a), apoC-III, and ANGPTL3 reduce their targets by 50–92% in early trials, but outcome studies are not yet complete.\u003c\/li\u003e\n\u003cli\u003eThe REDUCE-IT trial found that 4 grams daily of prescription icosapent ethyl lowered cardiovascular mortality by 25% in high-risk patients with elevated triglycerides.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eIntroduction: The Limits of Current Treatment\u003c\/h2\u003e\n\n\u003cp\u003eHeart disease remains the leading cause of death worldwide, despite major progress in prevention and treatment over recent decades. The main treatable culprit is dyslipidemia—an unhealthy balance of fats in the blood—and the standard approach has been to lower \"bad\" LDL cholesterol using drugs called statins. This strategy works: for every 38.7 mg\/dL reduction in LDL cholesterol, major vascular events drop by 23%. Yet there's a serious problem: many patients still remain at high risk even when taking these medications.\u003c\/p\u003e\n\n\u003cp\u003eA recent European survey found that only one-third of patients taking lipid-lowering drugs actually reach the recommended LDL cholesterol target of under 70 mg\/dL. Part of the issue is that patients don't always take their medications as prescribed. But even among those who do, significant risk remains. A newer class of drugs called PCSK9 inhibitors (given as injections) can reduce LDL cholesterol by 51% on top of statins and lower additional cardiovascular risk by 15%—but these drugs are expensive, which limits their widespread use.\u003c\/p\u003e\n\n\u003cp\u003eBecause of these gaps, researchers are now focusing on two other risk factors that statins barely touch: lipoprotein(a), known as Lp(a), and triglycerides (TG), a type of fat in the blood. Using a research technique called Mendelian randomization—which uses genetic information to determine cause-and-effect relationships—scientists have established that elevated levels of both are independent, causal risk factors for cardiovascular disease. Importantly, these risks persist even when LDL cholesterol is well controlled with statin therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"lpa\"\u003eLipoprotein(a): The Hidden Risk Factor\u003c\/h2\u003e\n\n\u003ch3\u003eWhat Is Lp(a) and How Does It Work?\u003c\/h3\u003e\n\n\u003cp\u003eLipoprotein(a), or Lp(a), is a unique particle that looks like an LDL cholesterol particle but has an extra protein attached to it called apolipoprotein(a). This protein is produced by the LPA gene in the liver and comes in many different sizes, ranging from 200 to 800 kDa. People with smaller versions of this protein tend to have higher Lp(a) levels in their blood.\u003c\/p\u003e\n\n\u003cp\u003eYour Lp(a) level is largely determined by your genetics. In fact, genetic variation in the LPA gene explains about 91% of the variation in Lp(a) levels between people. Diet and lifestyle choices have very little influence on it. Lp(a) is also a major carrier of oxidized phospholipids (OxPL)—molecules that stimulate inflammation and contribute to the buildup of plaque in arteries.\u003c\/p\u003e\n\n\u003cp\u003eDespite decades of research, scientists still don't fully understand exactly how Lp(a) is assembled, how it causes disease, or how it is cleared from the body. But the evidence linking it to heart disease is strong.\u003c\/p\u003e\n\n\u003ch3\u003eWhat the Research Shows: Lp(a) and Heart Disease Risk\u003c\/h3\u003e\n\n\u003cp\u003eMultiple lines of evidence have identified Lp(a) as a risk factor for both atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis (narrowing of the heart's main valve). A recent meta-analysis found a statistically independent, almost linear relationship between Lp(a) levels and cardiovascular risk in patients already taking statins—meaning higher Lp(a) means higher risk, even when LDL is controlled.\u003c\/p\u003e\n\n\u003cp\u003eRemarkably, Lp(a) has a stronger association with death from any cause than LDL cholesterol does, for a similar increase in cholesterol content. This suggests that Lp(a)'s harmful effects go beyond just its cholesterol content. Researchers calculated that reducing Lp(a) by 65.7 mg\/dL would have the same effect on reducing coronary heart disease as lowering LDL cholesterol by 38.7 mg\/dL—though these estimates are based on genetic epidemiological studies, so caution is warranted.\u003c\/p\u003e\n\n\u003cp\u003eGuidelines from the European Atherosclerosis Society recommend keeping Lp(a) levels below 50 mg\/dL, which is below the 80th percentile of the Danish Caucasian population. The threshold for increased risk may be lower depending on the test used and the population being studied.\u003c\/p\u003e\n\n\u003cp\u003eSpecific populations have notably higher Lp(a) levels:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSouth Asians and Latin Americans\u003c\/strong\u003e have higher Lp(a) concentrations and increased risk of heart attack compared to Africans, Arabs, Chinese, Europeans, and Southeast Asians\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e24% of 531,144 patients\u003c\/strong\u003e tested in a US referral laboratory had Lp(a) levels above 50 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e46% of 247 patients\u003c\/strong\u003e with familial hypercholesterolemia (FH) in Spain had levels above 50 mg\/dL\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne concerning finding: statins can actually increase Lp(a) levels by 9–20%, likely because they increase LPA gene expression and apo(a) production. Meanwhile, drugs targeting PCSK9 (like Evolocumab) or apoB (Mipomersen) have been shown to reduce Lp(a) levels. However, a 14% Lp(a) reduction with Evolocumab did not affect arterial wall inflammation, suggesting that greater reductions may be needed for clinical benefit.\u003c\/p\u003e\n\n\u003ch3\u003eNew Drugs Targeting Lp(a)\u003c\/h3\u003e\n\n\u003cp\u003eExperimental therapies are being developed that block the liver from producing apo(a) in the first place. These drugs, called antisense oligonucleotides (ASOs), are given as subcutaneous injections (under the skin). They work by binding to the messenger RNA (mRNA) that carries the genetic instructions for making apo(a), causing that message to be destroyed before any protein can be made.\u003c\/p\u003e\n\n\u003cp\u003eA newer version of this technology, called a ligand-conjugated ASO, is chemically modified to be taken up more efficiently by liver cells. This version—IONIS-APO(a)-LRX—is roughly \u003cstrong\u003e30 times more potent\u003c\/strong\u003e than the original formulation.\u003c\/p\u003e\n\n\u003cp\u003eClinical trial results have been impressive:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhase I trials:\u003c\/strong\u003e Weekly injections in individuals with elevated Lp(a) produced dose-dependent reductions in Lp(a) levels of up to \u003cstrong\u003e92%\u003c\/strong\u003e, along with a 72% decrease in oxidized phospholipids, a 20% reduction in LDL cholesterol, and a 19% reduction in apoB\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhase II trials:\u003c\/strong\u003e Among patients with established cardiovascular disease and elevated Lp(a), \u003cstrong\u003e98%\u003c\/strong\u003e of those receiving 20 mg weekly reached Lp(a) levels below 50 mg\/dL, and \u003cstrong\u003e81%\u003c\/strong\u003e of those receiving 60 mg monthly achieved the same target, with no safety concerns\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA Phase III cardiovascular outcome study is now planned. However, no evidence yet proves that lowering Lp(a) actually reduces heart attacks and strokes—that remains the critical next step to validate Lp(a) as a causal risk factor worth treating.\u003c\/p\u003e\n\n\u003ch2 id=\"apoc3\"\u003eApolipoprotein C-III: A Key Regulator of Triglycerides\u003c\/h2\u003e\n\n\u003ch3\u003eWhat Is ApoC-III and What Does It Do?\u003c\/h3\u003e\n\n\u003cp\u003eApolipoprotein C-III (apoC-III) is a protein produced mainly in the liver and, to a lesser extent, in the intestine. Once in the bloodstream, it attaches to HDL cholesterol (the \"good\" cholesterol) and to triglyceride-rich lipoproteins (TRLs), which include chylomicrons, VLDL, and IDL—particles that carry fat through the blood.\u003c\/p\u003e\n\n\u003cp\u003eAnimal studies show that apoC-III raises triglyceride levels through several mechanisms: it inhibits lipoprotein lipase (LPL) and hepatic lipase (HL)—enzymes that normally break down triglycerides—and it increases the liver's production of VLDL. It also interferes with the removal of triglyceride-rich particles from the blood by blocking their binding to LDL receptors. Beyond fat metabolism, laboratory studies suggest apoC-III may directly activate endothelial cells (the lining of blood vessels) and promote monocyte adherence—both early steps in atherosclerosis—and it also appears to play a role in insulin resistance and pancreatic beta-cell function.\u003c\/p\u003e\n\n\u003ch3\u003eGenetic Evidence Linking ApoC-III to Heart Disease\u003c\/h3\u003e\n\n\u003cp\u003eThe genetic evidence for apoC-III's importance is compelling. People with gain-of-function (GOF) mutations in the APOC3 gene—meaning their bodies make too much apoC-III—have plasma triglycerides that are \u003cstrong\u003e32% higher\u003c\/strong\u003e than their relatives without the mutation. Conversely, people with loss-of-function (LOF) mutations, who produce less apoC-III, enjoy two benefits: \u003cstrong\u003e39% lower triglycerides\u003c\/strong\u003e and a \u003cstrong\u003e40% lower risk of heart disease\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eEven more striking: a decrease of just 1 mg\/dL of apoC-III in the blood is associated with a \u003cstrong\u003e4% reduction in cardiovascular risk\u003c\/strong\u003e, after adjusting for age and sex. Researchers studying people with near-absent apoC-III levels found they had slightly further reduced triglycerides, markedly increased HDL cholesterol, and similar LDL cholesterol compared to those with partial deficiency.\u003c\/p\u003e\n\n\u003ch3\u003eVolanesorsen: The First ApoC-III Drug\u003c\/h3\u003e\n\n\u003cp\u003eThe main strategy to block apoC-III production uses antisense oligonucleotides (ASOs), similar to the approach used for Lp(a). The leading drug, Volanesorsen (also known as ISIS 304801), was initially developed for rare genetic disorders: familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL), both characterized by dangerously high triglyceride levels.\u003c\/p\u003e\n\n\u003cp\u003eIn Phase II trials with weekly injections of 300 mg, Volanesorsen produced dramatic changes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eapoC-III reduced by \u003cstrong\u003e80%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eTriglycerides reduced by \u003cstrong\u003e71%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHDL cholesterol increased by \u003cstrong\u003e46%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eNon-HDL cholesterol reduced by \u003cstrong\u003e11%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLDL cholesterol increased by \u003cstrong\u003e118%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThat last finding is surprising and concerning. Phase III studies (APPROACH and COMPASS) in patients with FCS or severe hypertriglyceridemia (TG \u0026gt; 500 mg\/dL) showed an 84% reduction in apoC-III and greater than 70% reduction in triglycerides with weekly 300 mg doses. In FCS patients (who start with very low LDL at baseline of 28.2 mg\/dL), LDL cholesterol increased by 139%, though non-HDL cholesterol decreased overall.\u003c\/p\u003e\n\n\u003cp\u003eVolanesorsen also showed promise for improving insulin sensitivity, suggesting potential use in type 2 diabetes. However, the drug was found to increase the risk of thrombocytopenia (dangerously low blood platelet counts) in FCS patients, so FDA approval currently depends on the outcomes of ongoing clinical trials. Two studies are tracking long-term safety: the BROADEN study follows 60 FPL patients for 1–3 years with results expected in 2019, and the APPROACH Open Label Study follows FCS patients for 65 weeks, with completion estimated in 2020.\u003c\/p\u003e\n\n\u003ch3\u003eA Second-Generation ApoC-III Drug with Fewer Side Effects\u003c\/h3\u003e\n\n\u003cp\u003eA next-generation ligand-based ASO (ISIS 678354) shows similar benefits without the problematic LDL increase. In Phase I\/II trials with 30 mg weekly, patients experienced:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eapoC-III reduced by \u003cstrong\u003e84%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eTriglycerides reduced by \u003cstrong\u003e71%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHDL cholesterol increased by \u003cstrong\u003e56%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLDL cholesterol decreased by \u003cstrong\u003e17%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBoth multiple-dose groups—whether weekly or monthly—showed reduced LDL cholesterol. A Phase II trial in patients with hypertriglyceridemia and established cardiovascular disease is expected to be completed this year.\u003c\/p\u003e\n\n\u003ch2 id=\"angptl3\"\u003eANGPTL3: A New Target for Multiple Lipid Problems\u003c\/h2\u003e\n\n\u003ch3\u003eWhat Is ANGPTL3?\u003c\/h3\u003e\n\n\u003cp\u003eAngiopoietin-like protein 3 (ANGPTL3) is a protein produced almost exclusively in the liver. Its job is to regulate how triglycerides are distributed between muscle tissue (where they're burned for energy) and fat tissue (where they're stored). It does this by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), two enzymes that break down fats in the blood.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, studies in mice suggest that inactivating ANGPTL3 changes the way apoB-containing lipoproteins (the harmful fat-carrying particles) are cleared from the circulation—without directly involving the usual LDL receptor pathway. That's important because most cholesterol-lowering drugs work through LDL receptors, so ANGPTL3 provides an alternative approach for patients who don't respond adequately to those drugs.\u003c\/p\u003e\n\n\u003ch3\u003eGenetic Evidence for ANGPTL3\u003c\/h3\u003e\n\n\u003cp\u003eComplete ANGPTL3 deficiency in humans is rare but very revealing. It causes a condition called familial combined hypolipidemia, characterized by dramatically reduced levels of all three major lipids:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTriglycerides reduced by \u003cstrong\u003e62%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLDL cholesterol reduced by \u003cstrong\u003e48%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHDL cholesterol reduced by \u003cstrong\u003e46%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePeople with two copies of loss-of-function mutations also have higher LPL activity, lower free fatty acids, and increased insulin sensitivity compared to non-carriers. A study by Dewey and colleagues found that 246 heterozygous carriers (one copy of the mutation) had \u003cstrong\u003e27% lower triglycerides\u003c\/strong\u003e, \u003cstrong\u003e9% lower LDL cholesterol\u003c\/strong\u003e, unchanged HDL cholesterol, and a \u003cstrong\u003e41% reduced risk of coronary artery disease\u003c\/strong\u003e compared to 58,089 non-carriers. A meta-analysis of 19 studies covering 21 different loss-of-function variants found a \u003cstrong\u003e34% lower risk of coronary artery disease\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eDrugs Targeting ANGPTL3\u003c\/h3\u003e\n\n\u003cp\u003eTwo types of drugs targeting ANGPTL3 are in early development: monoclonal antibodies (which block the protein in the bloodstream) and antisense oligonucleotides (which block the liver from producing it in the first place). These approaches could produce different results, since antibodies only neutralize protein circulating in the blood while ASOs also block any potential functions of the protein inside cells.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEvinacumab (monoclonal antibody):\u003c\/strong\u003e In healthy adults with moderate hypertriglyceridemia or elevated LDL cholesterol (above 100 mg\/dL), a single intravenous dose of 20 mg\/kg reduced:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTriglycerides by \u003cstrong\u003e50%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLDL cholesterol by \u003cstrong\u003e23%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHDL cholesterol by up to \u003cstrong\u003e18%\u003c\/strong\u003e (after 15 days compared to placebo)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn an open-label study, 9 patients with homozygous familial hypercholesterolemia (a severe genetic condition causing extremely high LDL from birth) received Evinacumab and achieved a mean reduction of \u003cstrong\u003e47% in triglycerides\u003c\/strong\u003e, \u003cstrong\u003e49% in LDL cholesterol\u003c\/strong\u003e, and \u003cstrong\u003e36% in HDL cholesterol\u003c\/strong\u003e. This proves the drug works even in patients without functional LDL receptors. Phase II trials are now recruiting patients with heterozygous FH who still have high cholesterol despite maximal statin therapy, and those at risk for acute pancreatitis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIONIS-ANGPTL3-LRX (antisense oligonucleotide):\u003c\/strong\u003e Phase I trials in healthy volunteers with hypertriglyceridemia, using 60 mg weekly, resulted in reductions of:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eANGPTL3 protein by \u003cstrong\u003e85%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eTriglycerides by \u003cstrong\u003e50%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLDL cholesterol by \u003cstrong\u003e33%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHDL cholesterol by \u003cstrong\u003e27%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA Phase II trial in patients with type 2 diabetes was completed in April 2019, with results awaited. Altogether, both approaches are remarkably effective—at the highest doses, they essentially recreate the lipid profile of people born with ANGPTL3 deficiency.\u003c\/p\u003e\n\n\u003ch2 id=\"omega3\"\u003eOmega-3 Fatty Acids: Fish Oil's Evolving Role\u003c\/h2\u003e\n\n\u003ch3\u003eTypes of Omega-3 Fatty Acids\u003c\/h3\u003e\n\n\u003cp\u003eThree omega-3 fatty acid (OM3FA) supplements are currently approved by the FDA for treating severe hypertriglyceridemia (triglycerides above 500 mg\/dL). Despite decades of largely inconclusive studies on their cardiovascular benefits, omega-3s are still thought to protect the heart. Current research focuses on finding the most effective dose, combinations of fatty acids, and chemical formulations for optimal absorption.\u003c\/p\u003e\n\n\u003cp\u003eThe main omega-3 fatty acids in oily fish are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEPA (eicosapentaenoic acid):\u003c\/strong\u003e The most studied; it reduces inflammation, inhibits cholesterol crystal formation, reduces the oxidative properties of harmful lipoproteins, and increases plaque stability\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDHA (docosahexaenoic acid):\u003c\/strong\u003e Along with EPA, reduces triglycerides with various effects on LDL and HDL cholesterol\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDPA (docosapentaenoic acid):\u003c\/strong\u003e Can be converted into DHA and EPA; also has beneficial effects on heart health and lipid metabolism in mice, but is less studied because pure DPA is expensive and hard to obtain\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThree FDA-approved prescription omega-3 drugs exist for severe hypertriglyceridemia:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOM3FA ethyl esters (Lovaza\/Omtryg):\u003c\/strong\u003e Contains both EPA and DHA; reduces triglycerides by about 45%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIcosapent ethyl (Vascepa):\u003c\/strong\u003e Contains only EPA; reduces triglycerides by 18–27%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOmega-3 carboxylic acids (Epanova):\u003c\/strong\u003e Contains a mixture of EPA, DHA, and DPA; reduces triglycerides by about 31%\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eWhat the Studies Show About Heart Outcomes\u003c\/h3\u003e\n\n\u003cp\u003eFor years, the evidence on omega-3s and cardiovascular outcomes was disappointing. A large meta-analysis of 77,917 participants, the ASCEND study (over 15,000 patients with diabetes), and the VITAL study (a primary prevention trial with more than 25,000 participants) all failed to show major cardiovascular benefits from omega-3 supplementation.\u003c\/p\u003e\n\n\u003cp\u003eThen came the surprising REDUCE-IT trial. This study showed a \u003cstrong\u003e25% reduction in cardiovascular mortality\u003c\/strong\u003e among patients taking 4 grams of Vascepa (icosapent ethyl) daily on top of statin therapy. After one year, the drug lowered plasma triglycerides by 18%, with only a slight 3% increase in LDL cholesterol.\u003c\/p\u003e\n\n\u003cp\u003eBased on these findings, the American Diabetes Association updated its \"Standards of Medical Care in Diabetes\" and now recommends Vascepa for diabetic patients with ASCVD, or for patients on statins with elevated triglycerides, to reduce cardiovascular risk. Importantly, the molecular reasons for this success are still unclear and likely go beyond merely lowering triglycerides.\u003c\/p\u003e\n\n\u003ch3\u003eOngoing Research\u003c\/h3\u003e\n\n\u003cp\u003eThe short-term EVAPORATE study is evaluating Vascepa in 80 statin-treated patients with elevated triglycerides (200–499 mg\/dL), tracking the progression of low-attenuation plaque volume (a measure of dangerous arterial plaque) over 9–18 months. Several long-term studies using different omega-3 formulations and dosages (1.8–4 g daily) are also underway:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSTRENGTH:\u003c\/strong\u003e Testing omega-3 carboxylic acids in statin patients with triglycerides above 180 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRESPECT-EPA:\u003c\/strong\u003e Testing EPA in patients with stable coronary artery disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOMEMI:\u003c\/strong\u003e Testing omega-3s in patients who have survived a heart attack\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe first long-term study is expected to be completed in 2020. Additionally, MAT9001 (containing EPA and DPA) is in Phase II trials for severe hypertriglyceridemia, with data comparing it to Vascepa expected by the end of 2020.\u003c\/p\u003e\n\n\u003ch2 id=\"future\"\u003eFuture Perspectives: What's on the Horizon\u003c\/h2\u003e\n\n\u003cp\u003eFor a significant proportion of patients, LDL cholesterol reduction with statins—and possibly ezetimibe and bile-acid sequestrants—is not enough to eliminate cardiovascular risk. Further LDL reduction is possible with PCSK9 inhibition, but the high cost of currently approved monoclonal antibodies limits widespread use. Several alternatives may provide relief in the future, including siRNA-based drugs (like LIB003) or ASOs against PCSK9 (like SPC5001). Another experimental drug, Bempedoic acid (currently awaiting FDA approval), can lower LDL cholesterol by up to 21% and may offer a more affordable option on top of statins.\u003c\/p\u003e\n\n\u003cp\u003eThe failure of therapies that target HDL cholesterol has shifted focus toward treating elevated Lp(a) and triglyceride-rich lipoproteins. Recent genetic evidence supporting Lp(a) and triglycerides as causal risk factors, combined with advances in monoclonal antibody and antisense technology, has driven major progress in developing new treatments for residual cardiovascular risk.\u003c\/p\u003e\n\n\u003cp\u003eKey challenges remain. The initial concern that ASOs against apoC-III increase LDL cholesterol appears solved with the new generation formulation, but the risk of low platelet counts (thrombocytopenia) still needs to be resolved. Notably, this side effect appears related to apoC-III itself, not the ASO technology. The observed reduction in HDL cholesterol following ANGPTL3 targeting was expected based on human genetics—and importantly, genetic data also show a reduced risk of heart disease despite this HDL reduction.\u003c\/p\u003e\n\n\u003cp\u003eASOs and monoclonal antibodies do require subcutaneous injections or intravenous administration, which some patients find inconvenient. However, these injected therapies offer certain advantages over daily oral medications, particularly for patients who struggle with adherence to daily pill regimens.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThis review article summarizes early-stage research, and several important caveats apply. First, most of the drugs discussed are still in Phase I, II, or early Phase III trials—meaning we don't yet know if lowering Lp(a), apoC-III, or ANGPTL3 actually translates into fewer heart attacks and strokes. The correlation between genetic variants that lower these targets and reduced risk is encouraging, but biology doesn't always match genetic predictions exactly.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the estimates comparing Lp(a) reduction to LDL reduction are based on genetic epidemiological studies, not direct clinical trials, and the actual cholesterol content of Lp(a) is estimated, not measured. Third, several drugs cause significant side effects—including the LDL-raising effect of Volanesorsen and the thrombocytopenia risk—which may limit their clinical utility. Finally, the ongoing trials discussed (BROADEN, APPROACH Open Label, REDUCE-IT, EVAPORATE, STRENGTH, RESPECT-EPA, OMEMI) have completion dates ranging from 2019 to 2020 and beyond; their results could change the conclusions summarized here.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you have cardiovascular disease, high cholesterol, or a family history of early heart attacks, here are key takeaways from this research:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your numbers.\u003c\/strong\u003e Standard cholesterol tests don't always measure Lp(a). If you have unexplained heart disease, a family history, or have had a stent or bypass at a young age, ask your doctor about having your Lp(a) level checked. Levels above 50 mg\/dL are considered elevated.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKeep taking your statins.\u003c\/strong\u003e Statins remain the foundation of treatment and reduce heart attacks and strokes by about 23% for every 38.7 mg\/dL of LDL lowered. Don't stop them because newer treatments are being developed—these are add-ons, not replacements.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about PCSK9 inhibitors if statins aren't enough.\u003c\/strong\u003e If you're at very high risk and your LDL cholesterol remains above target despite maximum statin therapy, PCSK9 inhibitors can reduce LDL by an additional 51% and cut cardiovascular risk by 15%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss triglyceride management with your doctor.\u003c\/strong\u003e Elevated triglycerides (above 500 mg\/dL) increase the risk of pancreatitis and heart disease. If you have high triglycerides and established heart disease or diabetes, ask about prescription omega-3 fatty acids—particularly icosapent ethyl (Vascepa)—which showed a 25% reduction in cardiovascular mortality in the REDUCE-IT trial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't rely on over-the-counter fish oil for heart protection.\u003c\/strong\u003e The studies that showed benefits used prescription-strength, FDA-approved omega-3 products at doses of 4 grams daily—much higher than typical supplements.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember that lifestyle still matters.\u003c\/strong\u003e While Lp(a) is largely genetic, triglycerides respond to diet, exercise, and weight loss. Reducing sugar and refined carbohydrates, limiting alcohol, and increasing physical activity can meaningfully lower triglycerides.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed about emerging therapies.\u003c\/strong\u003e Drugs targeting Lp(a) (like AKCEA-APO(a)-LRX), apoC-III, and ANGPTL3 are highly promising—reducing their targets by 50–92% in trials—but none are yet FDA-approved for routine use. Watch for the results of ongoing Phase III outcome trials that will determine if these drugs actually prevent heart attacks and strokes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is lipoprotein(a), and why should I be concerned about it?\u003c\/h3\u003e\n\u003cp\u003eLipoprotein(a), or Lp(a), is a particle similar to LDL cholesterol but with an extra protein attached. Your Lp(a) level is mostly genetic and barely affected by diet. Higher Lp(a) is linked to increased cardiovascular risk, even when LDL is controlled. A level above 50 mg\/dL is considered elevated.\u003c\/p\u003e\n\u003ch3\u003eIf I am already taking statins, do I still need to worry about my triglycerides?\u003c\/h3\u003e\n\u003cp\u003eYes. Statins lower LDL cholesterol effectively, but many patients still have elevated triglycerides, which are an independent causal risk factor for heart disease. Managing triglycerides through diet, exercise, and possibly prescription omega-3s may further reduce risk, but always discuss this with your doctor.\u003c\/p\u003e\n\u003ch3\u003eWhat new experimental drugs are being developed for high Lp(a)?\u003c\/h3\u003e\n\u003cp\u003eExperimental drugs called antisense oligonucleotides block the liver from making the apo(a) protein. In clinical trials, one such drug reduced Lp(a) by up to 92% in a phase I study, and most patients reached target levels in phase II trials. However, these drugs are not yet FDA-approved, and long-term outcome studies are still needed.\u003c\/p\u003e\n\u003ch3\u003eWhat is apoC-III, and why does blocking it lower triglycerides?\u003c\/h3\u003e\n\u003cp\u003eApoC-III is a protein that raises triglyceride levels by inhibiting enzymes that break down fats and by increasing the liver's production of fat particles. People with genetic mutations that reduce apoC-III have lower triglycerides and a lower risk of heart disease. Experimental drugs targeting apoC-III have shown dramatic triglyceride reductions, but safety concerns remain.\u003c\/p\u003e\n\u003ch3\u003eWhat is the role of omega-3 fatty acids in heart disease prevention?\u003c\/h3\u003e\n\u003cp\u003ePrescription omega-3s are FDA-approved for very high triglycerides. Most large trials did not show cardiovascular benefits, but the REDUCE-IT trial found a 25% reduction in cardiovascular mortality with icosapent ethyl at 4 grams daily in high-risk patients. Over-the-counter fish oil is not a proven substitute, as studies used prescription-strength products.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor about my cholesterol and heart risk?\u003c\/h3\u003e\n\u003cp\u003eAsk whether your Lp(a) level has been checked, especially if you have unexplained heart disease or a family history. Ask if non-statin medications like PCSK9 inhibitors are appropriate if your LDL remains high. Ask about triglyceride management if levels are above 500 mg\/dL. Keep taking your statins, as newer treatments are add-ons, not replacements.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e The Future of Lipid-Lowering Therapy\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Journal of Clinical Medicine, 2019, Volume 8, Article 1085; published 23 July 2019\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3390\/jcm8071085\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Always consult your healthcare provider about your specific medical condition and treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400024539292,"sku":null,"price":0.0,"currency_code":"CHF","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ch\/products\/the-next-generation-of-cholesterol-and-fat-lowering-treatments-what-patients-should-know-about-beyond-statin-therapies","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}